What key concepts about disseminated intravascular coagulation (DIC), thrombotic thrombocytopenic purpura (TTP), and sepsis should an ICU nurse understand when preparing for a CRNA (certified registered nurse anesthetist) interview?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Key Concepts for CRNA Interview: DIC, TTP, and Sepsis

Critical Distinction: These Are Different Diseases That Can Look Similar

The most important concept to understand is that DIC and TTP are fundamentally different pathophysiologic processes that both cause thrombocytopenia and microthrombi, but require completely different treatments—confusing them can be fatal. 1, 2

Core Pathophysiology Differences

DIC (Disseminated Intravascular Coagulation):

  • All coagulation systems activated simultaneously: coagulation cascade, fibrinolysis, and platelets 2
  • Consumption coagulopathy leading to both thrombosis AND bleeding
  • Triggered by sepsis, trauma, or other systemic insults through damage-associated molecular patterns (DAMPs) and inflammatory mediators 3
  • Results in widespread microvascular thrombosis with hemorrhagic complications from factor consumption

TTP (Thrombotic Thrombocytopenic Purpura):

  • Only platelets are markedly activated—coagulation factors remain normal 2
  • Caused by severe ADAMTS13 deficiency (<10% activity) 1
  • ADAMTS13 normally cleaves von Willebrand factor (VWF); without it, ultra-large VWF multimers cause spontaneous platelet aggregation
  • Two types: immune TTP (iTTP) from autoantibodies or congenital TTP (cTTP) from genetic mutations 1

The Diagnostic Challenge in Sepsis

Sepsis can cause BOTH conditions, and approximately 15% of DIC patients may have overlapping TMA features 2. This creates a critical diagnostic dilemma because:

  • Sepsis-induced DIC is common (occurs in most severe sepsis cases)
  • TTP is rare (1-6 cases per million annually) 4
  • Some septic patients develop DIC with secondary ADAMTS13 deficiency, creating a hybrid picture 5
  • The key is that true TTP has ADAMTS13 activity <10%, while septic DIC may have reduced but not severely deficient ADAMTS13 1

Diagnostic Approach: The Algorithm You Need

Step 1: Recognize the Clinical Presentation

Both conditions present with:

  • Thrombocytopenia
  • Microangiopathic hemolytic anemia (MAHA)—look for schistocytes on blood smear
  • Organ dysfunction

Key differentiating features:

Feature DIC TTP
Bleeding Prominent (oozing, difficult-to-control) [3] Minimal to absent
PT/aPTT Prolonged Normal [2]
Fibrinogen Low (consumed) Normal [2]
D-dimer Markedly elevated Mildly elevated or normal
Hyperfibrinolysis Present in most cases [2] Absent

Step 2: Apply Diagnostic Criteria

For Sepsis-Induced Coagulopathy (SIC)—The Screening Tool:

The SIC score is designed for early detection before overt DIC develops 6:

  • Platelet count
  • PT-INR
  • SOFA score (≥2 required for sepsis diagnosis)

SIC identifies patients at risk with ~30% mortality and high sensitivity for predicting progression to overt DIC 6

For Overt DIC Diagnosis:

Multiple criteria exist (JAAM DIC, ISTH overt-DIC, JSTH DIC) 7, 8. The JAAM criteria are more sensitive and diagnose earlier; ISTH criteria are stricter and diagnose later 7. Choose based on your clinical goal: JAAM for early treatment initiation, ISTH for definitive diagnosis 6.

Step 3: Measure ADAMTS13 Activity

ADAMTS13 activity measurement is the diagnostic gold standard for TTP 4.

  • ADAMTS13 <10% = TTP 1
  • Send this test immediately if TTP is suspected, but do not wait for results to treat if clinical suspicion is high 4
  • Normal or mildly reduced ADAMTS13 with coagulopathy = likely DIC

Treatment: Where Mistakes Kill Patients

If TTP is Suspected (Even Before ADAMTS13 Results)

Initiate the TTP triad immediately 4:

  1. Plasma exchange (reduced mortality from 15.7% to 3.9% in trials) 4
  2. Corticosteroids
  3. Caplacizumab (anti-VWF nanobody)

Add rituximab for immune suppression—modern protocols combining all four therapies have achieved mortality as low as 2.2% compared to 12.2% historically 4

Recombinant ADAMTS13 (Adzynma®) is now available as a newer option 1

If Septic DIC is Diagnosed

Treat the underlying infection first—this is non-negotiable 6, 9, 8

Adjunctive anticoagulant therapy (controversial but recommended in Japanese guidelines):

  • Antithrombin: Recommended (GRADE 1B) 8, particularly effective when baseline antithrombin activity ≤43% 6
  • Recombinant thrombomodulin: Recommended (GRADE 1B) 8, showed mortality benefit in meta-analyses of DIC patients 6
  • Heparin: No clear recommendation due to insufficient evidence 8

The evidence for anticoagulants is debated because large RCTs in "severe sepsis" failed, but post-hoc analyses and meta-analyses in patients specifically with septic DIC showed benefit 6. The key is patient selection—anticoagulants work in DIC, not in sepsis without DIC.

Two-Phase Management in Trauma-Related DIC

If discussing trauma (relevant for perioperative scenarios):

Early phase (hyperfibrinolytic):

  • Damage control resuscitation guided by viscoelastic testing (TEG/ROTEM)
  • Tranexamic acid for hemorrhage control 10

Late phase (thrombotic):

  • VTE prophylaxis
  • Consider targeted anticoagulation for microvascular thrombosis 10

Critical Pitfalls to Avoid

  1. Never delay TTP treatment waiting for ADAMTS13 results—mortality was nearly 100% before plasma exchange; survival now exceeds 95% with prompt treatment 1, 4

  2. Don't give plasma exchange for DIC—it's not indicated and wastes resources. DIC needs treatment of underlying cause plus potential anticoagulation 8

  3. Don't use anticoagulants in TTP—the problem is platelet aggregation from VWF, not thrombin generation 1

  4. Recognize that liver dysfunction confounds both DIC and SIC scoring because platelets and PT are affected by hepatic synthetic function 6

  5. Understand that "DIC" in sepsis exists on a spectrum: SIC (early, compensated) → overt DIC (late, decompensated). The two-step approach of screening with SIC then confirming with overt DIC criteria is the pragmatic standard 6

What CRNA Interviewers Want to Hear

Demonstrate you understand:

  • The mechanistic difference (ADAMTS13 deficiency vs. systemic coagulation activation)
  • Why ADAMTS13 testing is critical when thrombocytopenia + MAHA occur without clear coagulopathy
  • That TTP is a medical emergency requiring immediate plasma exchange, not a surgical/anesthetic problem
  • How perioperative stress, infection, or trauma can precipitate DIC
  • The importance of viscoelastic testing (TEG/ROTEM) in guiding resuscitation in acute DIC
  • That you would immediately consult hematology if ADAMTS13 <10% or TTP suspected

The bottom line: In a patient with thrombocytopenia and microangiopathic hemolysis, normal coagulation studies (PT/PTT/fibrinogen) should make you think TTP and call for ADAMTS13 testing and hematology consultation immediately, while abnormal coagulation studies with sepsis/trauma context suggest DIC requiring treatment of the underlying cause plus consideration of anticoagulant therapy.

References

Research

Disseminated intravascular coagulation.

Journal of intensive care, 2025

Research

Sepsis-induced disseminated intravascular coagulation with features of thrombotic thrombocytopenic purpura: a fatal fulminant syndrome.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2011

Research

Sepsis-Induced Coagulopathy and Disseminated Intravascular Coagulation.

Seminars in thrombosis and hemostasis, 2020

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.